HTG Announces Availability of 96 Max Gene Expression Assay at American Association of Cancer Research (AACR) Annual Meeting.
This 96 Max gene expression automated assay is based on HTG's proven qNPA ArrayPlate technology platform, which allows researchers to investigate a larger set of genes with greater precision than traditional gene expression assays. The technology allows academic researchers to quickly and efficiently measure gene expression levels of mRNA and miRNA in a variety of cell and tissue types including formalin-fixed, paraffin-embedded (FFPE) samples. The technology is ideal for detecting small, yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.
"HTG's new assay offering enables our academic researchers, who are conducting clinical and basic research, to essentially unlock information from sample types that were previously very challenging and near impossible to evaluate accurately," said BJ Kerns, VP Strategic Marketing and Business Development, HTG. "This is yet another expansion of our ArrayPlate platform. We devised this unique testing format to accommodate the needs of academic researchers who are evaluating tumor stratification, pathway and outcome schemes, as well as chemosensitivity."
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 20, 2009|
|Previous Article:||Mavent, QuestSoft Alliance Helps Lenders Meet Secondary Market Demands.|
|Next Article:||Carl Lamm Holding AB: New Date for Interim Report Regarding Q3, January-March 2009.|